Bora Biologics just gave San Diego's biotech scene a serious flex, cutting the ribbon on a $30 million expansion of its FDA-registered manufacturing campus in Sorrento Valley. The upgrade adds large-scale single-use bioreactors and refreshed purification lines, a combo the company says will significantly boost its U.S. biologics manufacturing capacity and get the site ready for commercial 2,000-liter runs. The ceremony pulled in company leaders, community partners, and San Diego Mayor Todd Gloria.
What the build-out includes
The board-approved project adds roughly 8,075 square feet of GMP manufacturing space, along with new upstream and downstream processing suites. Once fully online, the expansion will house 2,000-liter single-use trains and advanced downstream equipment, according to a press release from Newswire.
Company leaders and partners
John R. Mosack, general manager and vice president of operations at the San Diego site, said, "With this expansion, we can now offer our customers 2000-liter commercial manufacturing capacity." Mayor Todd Gloria, in remarks included in the same release, praised the local impact of the investment. The project brought in a lineup of specialist partners, including Cytiva for bioreactor technology, cGMPnow for process engineering, and DPR Construction for the buildout, details that appear in the Newswire announcement.
Local impact and the region's life-sciences cluster
San Diego regularly ranks among the country’s top life-sciences markets, and adding manufacturing capacity like this helps keep late-stage and commercial work close to home instead of sending it out of state. The San Diego Regional EDC points to the sector’s overall scale and its central role in local jobs and regional investment.
Already lining up work
Bora has already been tapped to manufacture NYPOZI™, a biosimilar, in partnership with InvaGen Pharmaceuticals, according to industry reporting from PharmaSource. The manufacturing win follows organizational changes after the CDMO business was folded into Tanvex, a transition that industry outlets say has sped up Bora’s push to expand its U.S. capacity, coverage that appears in FiercePharma.
Why it matters
For San Diego biotechs trying to move products from late-stage trials to full commercial supply, having local 2,000-liter capacity removes a major logistics headache and can tighten development timelines. Company leaders say the upgrade will help bring more clinical and commercial work into the region, support local jobs, and feed into the broader life-sciences growth story playing out across the county.
